Tira exclusively launches Korean skincare brand Dr. Melaxin in India
Reliance Retail’s beauty platform Tira has added Dr. Melaxin to its India portfolio through an exclusive omnichannel launch, selling the Korean brand online and in select stores. The rollout is led by its Peel Shot exfoliating ampoule range.
What happened
Reliance Retail’s Tira has exclusively launched South Korean K-beauty label Dr. Melaxin in India through its online platform and select stores, led by the Peel
Key facts
- Over 20 million app downloads
- Delivery coverage to more than 98% of India’s pincodes
- Jio World Plaza flagship spans over 6,200 sq. ft.
- 8-free clean formulation standard
- Clinical results reported within four weeks
Why this matters
Dr. Melaxin demonstrates Tira’s value as an India entry partner for international beauty brands, strengthening its pipeline for further exclusive distribution and strategic brand alliances.
What to watch
- Dr. Melaxin review volume, average rating and repeat-purchase indicators for Peel Shot products.
- Search and social-media growth for 'Dr. Melaxin' and 'Peel Shot' in India.
- Expansion from select Tira stores into a broader store network or additional SKUs.
- Pricing, discount depth and stock availability relative to competing Korean exfoliation brands.
- New K-beauty exclusivity announcements from Nykaa, Sephora India, Myntra and other beauty platforms.
- Prioritize Peel Shot sampling, dermatologist or creator education and clear exfoliant-use instructions to reduce trial barriers.
- Bundle Dr. Melaxin with complementary barrier-care, sunscreen and hydration products to increase attachment rates.
- Use app and store data to identify high-conversion cities, then expand physical availability selectively rather than nationally at once.
- Pursue further exclusive Korean skincare launches in adjacent concerns such as pigmentation, acne and skin-barrier repair.
- Competitors are likely to respond with K-beauty exclusives, quicker brand onboarding and promotional Korean skincare events.